Shop Longevity

Without a zinc atom it is completely inert. Not less active. Inert. The metal is not a supporting player here, it is half the molecule's identity.

It has no sequence and no CAS number, because it is not a molecule. It is an extract of calf thymus, still in clinical use across Russia, and that combination is genuinely unusual.

The alpha-MSH analogue that grew up and got approved as SCENESSE for a rare light-sensitivity disorder. The approved product is a subdermal implant in a clinic. This is not that, and the difference is the page.

Three amino acids your own liver assembles constantly. The cosmetic injectable evidence comes down to one 32-patient trial that landed at p equals 0.054, which is a number worth sitting with.

The least glamorous thing in the catalogue, and the one with a 35-trial human evidence base in osteoarthritis. A batch-variable hydrolysate, not a defined molecule, and honestly the best-evidenced item on this shelf.

GHK-Cu's synthetic cousin, one residue different, same copper habit. Its entire independent evidence base is a single study from 2007.

The sibling no sponsor ever developed and no regulator ever approved. Its published human record is substantially adverse-event case reports, which is a sentence worth reading twice.

Your mitochondria carry their own tiny genome, and it turns out that genome writes peptides. This is the famous one. The FDA searched six databases in 2026 and found no human trial data at all.

A tripeptide from your own plasma that refuses to travel without its copper atom. The strongest card in its file is a 1994 topical gel trial, and the one blinded aesthetic trial found no objective benefit.

Not a peptide, and your cells burn through it constantly anyway. It is the currency molecule of metabolism, and there is no controlled trial of the injectable form in healthy adults.

Four residues with a famous backstory that belongs to a different substance. The cited longevity studies used epithalamin, a bovine pineal extract, and the FDA has said plainly they are not the same thing.

A tetrapeptide that parks itself on cardiolipin, the lipid mitochondria keep for themselves. FDA approved it in September 2025 for Barth syndrome, on data from 12 patients, which is a story about rare-disease medicine.